Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen(196170) Issued Preliminary ‘Investment Warning’ Notice and Designated as ‘Investment Caution’ Stock on September 20 Following Over 200% Surge in a Year

Posted on September 19, 2024July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen(196170) Issued Preliminary ‘Investment Warning’ Notice and Designated as ‘Investment Caution’ Stock on September 20 Following Over 200% Surge in a Year

Source Fact: Financial Supervisory Service DART / 2024-09-19

Disclosure Type: Designation of Investment Caution Stock (Preliminary Warning for Investment Warning Stock)

💡 3-Second Summary

Due to a substantial year-on-year rally exceeding 200% and high trading volume concentration in specific accounts, biotech firm Alteogen has received a preliminary warning for an ‘Investment Warning Stock’ designation and will be temporarily classified as an ‘Investment Caution Stock’ for one day on September 20.

📊 1. [Summary of Core Disclosure Content and Major Figures]

  • Target Stock: Alteogen Co., Ltd. Common Stock (Ticker: 196170)
  • Effective Date of Caution Designation: September 20, 2024 (Designated as an Investment Caution Stock for 1 trading day)
  • Reason for Preliminary Warning: The closing price on September 19, 2024, moved up by more than 200% relative to the closing price from one year ago, fulfilling the quantitative thresholds for long-term price appreciation and high buying concentration from specific accounts.
  • Conditions for Final ‘Investment Warning Stock’ Designation: Within 10 trading days starting from the preliminary notice date (with the review window extending from the initial date of September 20 to October 07, 2024), the stock will be upgraded to an Investment Warning Stock on the following day if all the following three conditions are met on any specific evaluation day (T):
    1. The closing price on day T represents an increase of 200% or more compared to the closing price from one year ago.
    2. The closing price on day T is the highest closing price over the past 15 consecutive trading days (including day T).
    3. The number of days where the buy involvement rate of the top 10 accounts (considering market impact over the past 15 days) meets the regulatory threshold is 4 days or more.
  • Review Schedule Note: The review process begins on September 20, 2024. If the conditions are not satisfied, the review slides forward daily until October 07, 2024. The schedule remains subject to change upon potential trading suspensions.
  • Governing Regulation: Article 5-3 of the Market Surveillance Regulation and Article 3-3 of the Enforcement Rules of the same regulation.

📈 2. [Expert View: What This Disclosure Means for Investors]

This filing indicates a regulatory market intervention mechanism enforced by the Korea Exchange (KRX) to manage heightened price momentum and ensure investor protection against market overheating. It represents a systematic trading restriction triggered by asset volatility parameters rather than a development identifying an update in Alteogen’s underlying operational fundamental, clinical trials, or earnings performance.

The preliminary warning may generate a near-term psychological cooling effect on market participants during the caution designation window on September 20. If buying interest persists throughout the evaluation window (September 20 to October 07), forcing the stock to hit new 15-day highs alongside heavy trading concentration from the top 10 accounts, a formal upgrade to an ‘Investment Warning Stock’ could occur. Since progressing to the Investment Warning tier restricts credit leverage and implements a mandatory 100% upfront cash deposit rule, investors are advised to monitor the daily closing price vectors and high-volume account indicators carefully rather than trading purely on near-term upward momentum.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s powerful market rally has officially caught the attention of regulatory watchdogs, resulting in a preliminary ‘Investment Warning Stock’ alert. A stellar 200% year-on-year surge combined with concentrated accumulation from the top 10 accounts over the past 15 sessions has pushed the stock into the ‘Investment Caution’ bracket for September 20. While this temporary designation lasts for just one session, intraday volatility may spike. Given that the window for a potential upgrade to an Investment Warning status stays wide open until October 7, stepping back from emotional FOMO and objectively checking resistance barriers would be a safer route for portfolio protection.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Alteogen(196170) Files for Domestic Marketing Authorization of Eylea Biosimilar ‘EYZANFY Inj.’
Next Post: [Disclosure] ISU PETASYS (007660) to Host 2-Day ‘Overseas NDR’ for Global Institutional Investors in Singapore from Sep 23

Related Posts

[Disclosure] Alteogen (196170) Hits Jackpot: Signs KRW 867.5B Exclusive License Deal with Global Big Pharma Biogen for ALT-B4 Bio & Healthcare
[Disclosure] Alteogen (196170) Postpones Expected Date of Acquiring Altos Biologics Shares to Dec 31 Due to Schedule Adjustments in Subsidiary Merger Disclosures
[Disclosure] Alteogen (196170) Designated as Short-Selling Overheated Stock; Short-Selling Banned on May 19 Disclosures
[Disclosure] SK square(402340), Subsidiary SK hynix Confirms Nasdaq Listing and KRW 40T ADR Issuance Terms Disclosures
[Disclosure] Alteogen(196170) Lifted from ‘Investment Warning’ Status; Designated as ‘Investment Caution’ Stock with Re-designation Warning on October 11 Disclosures
[Disclosure] Alteogen(196170) to Hold IR at ‘J.P. Morgan 2026 Healthcare Conference’ in San Francisco, U.S. Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] SK square(402340), Subsidiary SK hynix Finalizes KRW 40T Paid-in Capital Increase with 2.72% PremiumJuly 10, 2026
  • [Disclosure] SK square(402340), Subsidiary SK hynix Finalizes Nasdaq Listing and 177.9M ADR Issuance VolumeJuly 10, 2026
  • [Disclosure] SK square(402340), Subsidiary SK hynix Confirms Nasdaq Listing and KRW 40T ADR Issuance TermsJuly 10, 2026
  • [Disclosure] SK Hynix(000660) Finalizes Terms for KRW 40 Trillion Paid-in Capital Increase Linked to Nasdaq ADRs (Issued at 2.72% Premium)July 10, 2026
  • [Disclosure] SK Hynix(000660) Finalizes Pricing and Timeline Terms for US Nasdaq ADR Issuance and Overseas ListingJuly 10, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme